MolDX: MGMT Promoter Methylation Analysis

This policy provides limited coverage for MGMT promoter methylation analysis in adult patients with high-grade malignant gliomas (e.g., GBM, anaplastic astrocytoma) when patients can tolerate temozolomide or radiation and when test results will be used to choose first-line adjuvant therapy (radiation vs chemotherapy or temozolomide vs other chemotherapy). Coverage is conditional on the assumption that therapy will be beneficial for the patient; payer-specific documentation or prior authorization requirements are not specified in the policy.

"MGMT promoter methylation analysis is covered for adult patients with high-grade malignant glioma (e."

Sign up to see full coverage criteria, indications, and limitations.